The Take-OverDoes everyone hear understand this deal ? "The LOI stipulates that the assets will be purchased from RepliCel in exchange for an 8-per-cent royalty on all gross profits earned by the purchaser in relation to the sale of DermaPrecise, RCH, RCT and RCS, or their improvements, after completion of the proposed transaction, up to a maximum of $160,922,238 (U.S.), or a new number which would represent an equivalent of $2.00 (U.S.) per share. "
In this part of the N/R you are lead to believe the purchaser plans to sell the assets.
In other sections of the N/R you are lead to believe they will develop the assets and the shareholders get a 8% royalty:
"With the anticipated commercialization of the assets not set until 2025 to 2027,"
Which is it ???